At Grifols, we take pride in our innovative achievements, strong customer service, sterling safety record and adherence to the highest standards of honesty and professional ethics. We have an unwavering commitment to the development of safer and more effective blood and plasma therapies as well as innovative products designed for hospitals, laboratory professionals and healthcare providers.
Our company develops and produces therapies and products in three healthcare divisions: Bioscience therapies made from human plasma; Hospital products and pharmacy IV solutions; and Diagnostic tools for laboratory professionals.
Our U.S. Presence
Grifols has a strong presence in the United States, where our products and therapies are widely distributed. We own and operate 147 plasma donor centers, where we collect plasma from qualified individuals and send it to one of our three, state-of-the-art manufacturing facilities. There, specialized engineers and technicians are responsible for extracting fragile proteins from plasma and purifying them for use in one of our many protein therapies. Our manufacturing sites are located in Clayton, North Carolina; Los Angeles California; and Melville, New York.
The inspiration for present-day Grifols began in 1910 in Barcelona, Spain, in the pioneering research laboratories of hematologist Dr. Jose Antonio Grifols Roig. Dr. Grifols and his two sons incorporated Laboratorios Grifols in 1940 to advance their work in the developing fields of transfusion, blood banking and clinical analysis.
The laboratory focused its research on improving the process of blood transfusions and creating tools for clinical analysis. In 1943, the laboratory began researching the potential applications of lyophilization, or freeze-drying, and as it related to human blood products such as plasma.
Grifols patented this process in Spain and developed a lyophilizer as well as instrumentation to later inject this plasma into people. These products laid the foundations for the opening of the first private blood bank in Spain in 1945. In 1952, Grifols registered a patent on a new glucosaline solution and the company began industrial production on its first line of IV products.
At Grifols, we approach challenges and opportunities with the eyes of experience as well as through a fresh perspective that considers new ways of solving old problems. We combine experience, flexibility and original thinking to arrive at innovative solutions for patients, hospitals and healthcare professionals.
- Grifols sustains a full and active research and development program that has acquired more than 300 patents in over 30 countries for plasma-derived therapies alone, and some 200 official product registrations in more than 50 countries. Grifols serves healthcare professionals and patients in over 90 countries around the world.
- Our innovative spirit has led to the formation of our own engineering and design group that has custom designed machines and facilities for both Grifols and other bio-pharmaceutical companies throughout the world.
- Our plasma screening processes were the first approved by the FDA to use Nucleic Amplification Testing methods — a process that not only detects a whole virus, but can also detect non-infectious virus fragments.
- Our FDA-approved manufacturing facilities are among the most modern in existence and compare favorably with biological plants anywhere in the world.